Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy

Radium-223 dichloride (Ra-223) is the first bone-targeting agent showing improvement in overall survival in patients with castration-resistant prostate cancer (CRPC) and bone metastases. We aimed to assess feasibility of Ra-223 treatment in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Ten patients with primary bone metastases received Ra-223 following radical prostatectomy (RP). Changes in alkaline phosphatase (ALP) and prostate-specific antigen (PSA) were recorded, while pain intensity was evaluated using the self-reporting Brief Pain Inventory (BPI) questionnaire. Bone scintigraphy (BS) was performed to assess treatment response. Seven patients completed six cycles of Ra-223. Discontinuation was due to leuko- and lymphopenia, progressive lymph node metastasis or newly diagnosed liver metastasis. Treatment-related adverse events occurred in three patients and included leuko- and lymphopenia, fatigue, abdominal discomfort and nausea. Overall, a median decrease of 28% in ALP and a median decrease of 83% in PSA were noted at follow-up. However, PSA progressed in five patients at follow-up. Improvement of pain was observed in all patients (median decrease of 36% after 3 cycles and of 40% at the end of therapy). On BS, three patients showed remission, four had stable disease, and one showed progressive disease at follow-up. Our results suggest that Ra-223 for primary bone metastases in patients with mHSPC after RP is feasible and alleviates pain. ALP, rather than PSA, may be a good marker for assessing treatment response. Ra-223 could therefore be taken into consideration as part of a multimodal approach for carefully selected patients with advanced prostate cancer.

Oncotarget. 2017 Jul 4;8(27):44131-44140. doi: 10.18632/oncotarget.17311.

Wenter V1, Herlemann A2, Fendler WP1, Ilhan H1, Tirichter N1, Bartenstein P1,3, Stief CG2,3, la Fougère C4,5, Albert NL1,Rominger A1, Gratzke C2,3.

Author information

1Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany.
2 Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany.
3 Comprehensive Cancer Center, Ludwig-Maximilians-University of Munich, Munich, Germany.
4 Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University, Tuebingen, Germany.
5 German Cancer Consortium, German Cancer Research Center Partner Site Tuebingen, Tuebingen, Germany.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.